Loading company…
Shanghai-based Mabwell develops macromolecular drugs, including monoclonal antibodies and antibody-drug conjugates.
Based in Shanghai, China, and established in 2017, Mabwell develops macromolecular drugs such as monoclonal antibodies and long-acting recombinant proteins for oncology, immunology, ophthalmology and orthopedics. It sells commercialized drugs in China mainly through third-party distributors. The company listed on the Shanghai Stock Exchange in January 2022 and raised over HKD 1.30 billion in a Hong Kong IPO in April 2026.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in